Accelerating Europe's Progress in CNS Gene Therapy

11 - 13 July | PARIS, FRANCE

”Really great presentations together with the convenience of remote attendance. The conference was a really great way to get up to speed on the latest in gene therapy of neurological disorders."
Johanne Kaplan, Chief Development Officer, ProMIS Neurosciences

“Overall great content and great ability to connect with relevant partners in the space. Excellent content, ample opportunity for learning and and the ability to connect with current and new partners in the GT space.”
Zach Carr, Biologics & Drug Delivery Program Manager, ClearPoint Neuro Inc.

“Phenomenal speakers and very intuitive, user-friendly software. Great opportunity to learn about cutting-edge gene therapy research in various neurological disorders.”
Jennifer Franks, Scientist, Bridgebio

Accelerating Europe's Progress in CNS Gene Therapy

Navigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic

With systemic toxicity challenges plaguing the AAV field, low-dose CNS indications are an ideal target for gene therapy. The plethora of neurological indications dominating gene therapy pipelines vary from rare neurological disorders to more common diseases including Parkinson’s, epilepsy and neurodevelopmental disorders.

As programs advance globally, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the field’s definitive forum to showcase the European landscape’s progress and specific regulatory challenges. Gene therapy developers from all of the world, including Europe’s brightest minds in CNS gene therapy, will unite in Paris to share their research progress and host an industry-dedicated discussion.

View the world-class speaker faculty and topics for discussion here